Vesicare set to succeed Prograf as Astellas' top US product
This article was originally published in Scrip
Executive Summary
Astellas expects the overactive bladder therapy Vesicare (solifenacin) to overtake its long-running top seller Prograf (tacrolimus) in the US this fiscal year, as the immunosuppressant continues to be battered by generic competition.